A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in period followed by a randomized period.
Epistemonikos ID: f61a7f5c81a77513e36acd25d602bf2bf73e2f3c
First added on: Jan 08, 2026